Clinical Trial Update: Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 [Phase 2]

View source ↗

Summary

Phase 2 trial update on GL101 aiming to reduce adverse ocular side effects from glaucoma medications in glaucoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Surface Disease

Drugs mentioned

• GL101

Snippet

Sponsor: Glia, LLC | Conditions: Ocular Surface Disease | Phase 2 | Status: COMPLETED